Inhibition of cyclooxygenase-2 prevents chronic and recurrent cystitis

EBioMedicine

Volumn 1, Issue 1, 2014, Pages 46-57

  Hannan, Thomas J ^a   Roberts, Pacita L ^b   Riehl, Terrence E ^a   van der Post, Sjoerd ^c   Binkley, Jana M ^a   Schwartz, Drew J ^a   Miyoshi, Hiroyuki ^a   Mack, Matthias ^d   Schwendener, Reto A ^e   Hooton, Thomas M ^f   Stappenbeck, Thaddeus S ^a   Hansson, Gunnar C ^c   Stenson, William F ^a   Colonna, Marco ^a   Stapleton, Ann E ^b   Hultgren, Scott J ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

^d UNIVERSITY OF REGENSBURG   (Germany)

^e UNIVERSITY OF ZURICH   (Switzerland)

^f UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Chronic infection; COX 2; Immunomodulatory therapy; Immunopathology; Mucosal immunology; Recurrent infection; UPEC; Urinary tract infection UTI; Uropathogenic E. coli

Indexed keywords

4 [5 (4 CHLOROPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOL 1 YL]BENZENESULFONAMIDE; 5 (4 CHLOROPHENYL) 1 (4 METHOXYPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOLE; BIOLOGICAL MARKER; CHEMOKINE RECEPTOR CCR2 ANTAGONIST; CIPROFLOXACIN; COLONY STIMULATING FACTOR 1; COTRIMOXAZOLE; CXCL1 CHEMOKINE; CYCLOOXYGENASE 2; INDOMETACIN; INTERLEUKIN 3; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; NITROFURANTOIN;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIUM CULTURE; CLINICAL ARTICLE; CONTROLLED STUDY; CYSTITIS; ESCHERICHIA COLI; FEMALE; FLOW CYTOMETRY; HISTOPATHOLOGY; HUMAN; IMMUNOFLUORESCENCE; IN SITU HYBRIDIZATION; LIQUID CHROMATOGRAPHY; MACROPHAGE; MONOCYTE; MOUSE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; PROTEOMICS; QUESTIONNAIRE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TANDEM MASS SPECTROMETRY; URINARY TRACT INFECTION; YOUNG ADULT;

EID: 84920927285     PISSN: None     EISSN: 23523964     Source Type: Journal    
DOI: 10.1016/j.ebiom.2014.10.011     Document Type: Article

References (64)

1. Gupta, K., Bhadelia, N., 2014. Management of urinary tract infections from multidrugresistant organisms. Infect. Dis. Clin. North Am. 28 (1), 49-59. http://dx.doi.org/10. 1016/j.idc.2013.10.002.
2. Foxman, B., 2014. Urinary tract infection syndromes: occurrence, recurrence, bacteriology, risk factors, and disease burden. Infect. Dis. Clin. North Am. 28 (1), 1-13. http://dx.doi.org/10.1016/j.idc.2013.09.003.
3. Schappert, S.M., Rechtsteiner, E.A., 2011. Ambulatory medical care utilization estimates for 2007. Vital Health Stat. 13 (169), 1-38.
4. Ferry, S.A., et al., 2004. The natural course of uncomplicated lower urinary tract infection in women illustrated by a randomized placebo controlled study. Scand. J. Infect. Dis. 36 (4), 296-301. http://dx.doi.org/10.1080/00365540410019642.
5. Mabeck, C.E., 1972. Treatment of uncomplicated urinary tract infection in non-pregnant women. Postgrad. Med. J. 48 (556), 69-75. http://dx.doi.org/10.1136/pgmj.48.556.69.
6. Hannan, T.J., et al., 2012. Host-pathogen checkpoints and population bottlenecks in persistent and intracellular uropathogenic Escherichia coli bladder infection. FEMS Microbiol. Rev. 36 (3), 616-648. http://dx.doi.org/10.1111/j.1574-6976.2012.00339.x.
7. Brumbaugh, A.R., Mobley, H.L., 2012. Preventing urinary tract infection: progress toward an effective Escherichia coli vaccine. Expert Rev. Vaccines 11 (6), 663-676. http://dx. doi.org/10.1586/erv.12.36.
8. Song, J., et al., 2009. TLR4-mediated expulsion of bacteria from infected bladder epithelial cells. Proc. Natl. Acad. Sci. U. S. A. 106 (35), 14966-14971. http://dx.doi.org/10.1073/pnas.0900527106.
9. Justice, S.S., et al., 2004. Differentiation and developmental pathways of uropathogenic Escherichia coli in urinary tract pathogenesis. Proc. Natl. Acad. Sci. U. S. A. 101 (5), 1333-1338. http://dx.doi.org/10.1073/pnas.0308125100.
10. Anderson, G.G., et al., 2003. Intracellular bacterial biofilm-like pods in urinary tract infections. Science 301 (5629), 105-107. http://dx.doi.org/10.1126/science.1084550.
11. Rosen, D.A., et al., 2007. Detection of intracellular bacterial communities in human urinary tract infection. PLoS Med. 4 (12), e329. http://dx.doi.org/10.1371/journal.pmed. 0040329.
12. Robino, L., et al., 2013. Detection of intracellular bacterial communities in a child with Escherichia coli recurrent urinary tract infections. Pathog. Dis. 68 (3), 78-81. http://dx.doi.org/10.1111/2049-632X.12047.
13. Robino, L., et al., 2014. Intracellular bacteria in the pathogenesis of Escherichia coli urinary tract infection in children. Clin. Infect. Dis. http://dx.doi.org/10.1093/cid/ciu634.
14. Schwartz, D.J., et al., 2011. Population dynamics and niche distribution of uropathogenic Escherichia coli during acute and chronic urinary tract infection. Infect. Immun. 79 (10), 4250-4259. http://dx.doi.org/10.1128/IAI.05339-11.
15. Duell, B.L., et al., 2012. Innate transcriptional networks activated in bladder in response to uropathogenic Escherichia coli drive diverse biological pathways and rapid synthesis of IL-10 for defense against bacterial urinary tract infection. J. Immunol. 188 (2), 781-792. http://dx.doi.org/10.4049/jimmunol.1101231.
16. Ingersoll, M.A., et al., 2008. G-CSF induction early in uropathogenic Escherichia coli infection of the urinary tract modulates host immunity. Cell. Microbiol. 10 (12), 2568-2578. http://dx.doi.org/10.1111/j.1462-5822.2008.01230.x.
17. Ragnarsdottir, B., et al., 2011. Genetics of innate immunity and UTI susceptibility. Nat. Rev. Urol. 8 (8), 449-468. http://dx.doi.org/10.1038/nrurol.2011.100.
18. Haraoka, M., et al., 1999. Neutrophil recruitment and resistance to urinary tract infection. J. Infect. Dis. 180 (4), 1220-1229. http://dx.doi.org/10.1086/315006.
19. Schiwon, M., et al., 2014. Crosstalk between sentinel and helper macrophages permits neutrophil migration into infected uroepithelium. Cell 156 (3), 456-468. http://dx. doi.org/10.1016/j.cell.2014.01.006.
20. Chan, C.Y., St John, A.L., Abraham, S.N., 2013. Mast cell interleukin-10 drives localized tolerance in chronic bladder infection. Immunity 38 (2), 349-359. http://dx.doi.org/10. 1016/j.immuni.2012.10.019.
21. Mulvey, M.A., et al., 1998. Induction and evasion of host defenses by type 1-piliated uropathogenic Escherichia coli. Science 282 (5393), 1494-1497. http://dx.doi.org/10. 1126/science.282.5393.1494.
22. Dhakal, B.K., Mulvey, M.A., 2012. The UPEC pore-forming toxin alpha-hemolysin triggers proteolysis of host proteins to disrupt cell adhesion, inflammatory, and survival pathways. Cell Host Microbe 11 (1), 58-69. http://dx.doi.org/10.1016/j.chom.2011. 12.003.
23. Mysorekar, I.U., Hultgren, S.J., 2006. Mechanisms of uropathogenic Escherichia coli persistence and eradication from the urinary tract. Proc. Natl. Acad. Sci. U. S. A. 103 (38), 14170-14175. http://dx.doi.org/10.1073/pnas.0602136103.
24. Mulvey, M.A., Schilling, J.D., Hultgren, S.J., 2001. Establishment of a persistent Escherichia coli reservoir during the acute phase of a bladder infection. Infect. Immun. 69 (7), 4572-4579. http://dx.doi.org/10.1128/IAI.69.7.4572-4579.2001.
25. Hannan, T.J., et al., 2010. Early severe inflammatory responses to uropathogenic E. coli predispose to chronic and recurrent urinary tract infection. PLoS Pathog. 6 (8), e1001042. http://dx.doi.org/10.1371/journal.ppat.1001042.
26. Schlager, T.A., et al., 2011. B cell infiltration and lymphonodular hyperplasia in bladder submucosa of patients with persistent bacteriuria and recurrent urinary tract infections. J. Urol. 186 (6), 2359-2364. http://dx.doi.org/10.1016/j.juro.2011.07.114.
27. Hansson, S., et al., 1990. Follicular cystitis in girls with untreated asymptomatic or covert bacteriuria. J. Urol. 143 (2), 330-332.
28. Stamm, W.E., et al., 1982. Diagnosis of coliform infection in acutely dysuric women. N. Engl. J. Med. 307 (8), 463-468. http://dx.doi.org/10.1056/NEJM198208193070802.
29. Murray, P.R., 1999. Manual of Clinical Microbiology, 7th ed. American Society for Microbiology, Washington, DC.
30. Schilling, J.D., et al., 2001. Bacterial invasion augments epithelial cytokine responses to Escherichia coli through a lipopolysaccharide-dependent mechanism. J. Immunol. 166 (2), 1148-1155. http://dx.doi.org/10.4049/jimmunol.166.2.1148.
31. Wright, K.J., Seed, P.C., Hultgren, S.J., 2005. Uropathogenic Escherichia coli flagella aid in efficient urinary tract colonization. Infect. Immun. 73 (11), 7657-7668, http://dx.doi. org/10.1128/IAI.73.11.7657-7668.2005.
32. Seiler, P., et al., 1997. Crucial role of marginal zone macrophages and marginal zone metallophils in the clearance of lymphocytic choriomeningitis virus infection. Eur. J. Immunol. 27 (10), 2626-2633. http://dx.doi.org/10.1002/eji.1830271023.
33. Zeisberger, S.M., et al., 2006. Clodronate-liposome-mediated depletion of tumourassociated macrophages: a new and highly effective antiangiogenic therapy approach. Br. J. Cancer 95 (3), 272-281. http://dx.doi.org/10.1038/sj.bjc.6603240.
34. Mack, M., et al., 2001. Expression and characterization of the chemokine receptors CCR2 and CCR5 in mice. J. Immunol. 166 (7), 4697-4704. http://dx.doi.org/10.4049/jimmunol.166.7.4697.
35. Bruhl, H., et al., 2007. Targeting of Gr-1+, CCR2+ monocytes in collagen-induced arthritis. Arthritis Rheum. 56 (9), 2975-2985. http://dx.doi.org/10.1002/art.22854.
36. Guiton, P.S., et al., 2013. Enterococcus faecalis overcomes foreign body-mediated inflammation to establish urinary tract infections. Infect. Immun. 81 (1), 329-339. http://dx.doi.org/10.1128/IAI.00856-12.
37. Hopkins, W.J., et al., 1998. Time course and host responses to Escherichia coli urinary tract infection in genetically distinct mouse strains. Infect. Immun. 66 (6), 2798-2802.
38. Lu, A., Wisniewski, J.R., Mann, M., 2009. Comparative proteomic profiling of membrane proteins in rat cerebellum, spinal cord, and sciatic nerve. J. Proteome Res. 8 (5), 2418-2425. http://dx.doi.org/10.1021/pr8010364.
39. Wisniewski, J.R., et al., 2009. Universal sample preparation method for proteome analysis. Nat. Methods 6 (5), 359-362. http://dx.doi.org/10.1038/nmeth.1322.
40. Boersema, P.J., et al., 2009. Multiplex peptide stable isotope dimethyl labeling for quantitative proteomics. Nat. Protoc. 4 (4), 484-494. http://dx.doi.org/10.1038/nprot.2009.21.
41. van der Post, S., et al., 2013. Site-specific O-glycosylation on the MUC2 mucin protein inhibits cleavage by the Porphyromonas gingivalis secreted cysteine protease (RgpB). J. Biol. Chem. 288 (20), 14636-14646. http://dx.doi.org/10.1074/jbc. M113.459479.
42. Cox, J., Mann, M., 2008. MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat. Biotechnol. 26 (12), 1367-1372. http://dx.doi.org/10.1038/nbt.1511.
43. Cox, J., et al., 2011. Andromeda: a peptide search engine integrated into theMaxQuant environment. J. Proteome Res. 10 (4), 1794-1805. http://dx.doi.org/10.1021/pr101065j.
44. Shannon, P., et al., 2003. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 13 (11), 2498-2504. http://dx.doi.org/10.1101/gr.1239303.
45. Jensen, L.J., et al., 2009. STRING 8-a global view on proteins and their functional interactions in 630 organisms. Nucleic Acids Res. 37, D412-D416. http://dx.doi.org/10.1093/nar/gkn760 (Database issue).
46. Bindea, G., et al., 2009. ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks. Bioinformatics 25 (8), 1091-1093. http://dx.doi.org/10.1093/bioinformatics/btp101.
47. Pfaffl, M.W., 2001. A new mathematical model for relative quantification in real-time RTPCR. Nucleic Acids Res. 29 (9), e45. http://dx.doi.org/10.1093/nar/29.9.e45.
48. Manieri, N.A., et al., 2012. Igf2bp1 is required for full induction of Ptgs2 mRNA in colonic mesenchymal stem cells in mice. Gastroenterology 143 (1), 110-121. http://dx.doi. org/10.1053/j.gastro.2012.03.037 (e10).
49. Schilling, J.D., Lorenz, R.G., Hultgren, S.J., 2002. Effect of trimethoprim-sulfamethoxazole on recurrent bacteriuria and bacterial persistence in mice infected with uropathogenic Escherichia coli. Infect. Immun. 70 (12), 7042-7049. http://dx.doi.org/10.1128/IAI.70. 12.7042-7049.2002.
50. Daley, J.M., et al., 2008. Use of Ly6G-specific monoclonal antibody to deplete neutrophils in mice. J. Leukoc. Biol. 83 (1), 64-70. http://dx.doi.org/10.1189/jlb.0407247.
51. Engel, D., et al., 2006. Tumor necrosis factor alpha- and inducible nitric oxide synthaseproducing dendritic cells are rapidly recruited to the bladder in urinary tract infection but are dispensable for bacterial clearance. Infect. Immun. 74 (11), 6100-6107. http://dx.doi.org/10.1128/IAI.00881-06.
52. Brandes, M., et al., 2013. A systems analysis identifies a feedforward inflammatory circuit leading to lethal influenza infection. Cell 154 (1), 197-212. http://dx.doi.org/10.1016/j.cell.2013.06.013.
53. Cubells, L., et al., 2008. Annexin A6-induced inhibition of cytoplasmic phospholipase A2 is linked to caveolin-1 export from the Golgi. J. Biol. Chem. 283 (15), 10174-10183. http://dx.doi.org/10.1074/jbc. M706618200.
54. Rhen, T., Cidlowski, J.A., 2005. Antiinflammatory action of glucocorticoids-new mechanisms for old drugs. N. Engl. J. Med. 353 (16), 1711-1723. http://dx.doi.org/10. 1056/NEJMra050541.
55. de Jongh, R., et al., 2009. The localization of cyclo-oxygenase immuno-reactivity (COX IIR) to the urothelium and to interstitial cells in the bladder wall. J. Cell. Mol. Med. 13 (9B), 3069-3081. http://dx.doi.org/10.1111/j.1582-4934.2008.00475.x.
56. de Jongh, R., et al., 2007. The effects of exogenous prostaglandins and the identification of constitutive cyclooxygenase I and II immunoreactivity in the normal guinea pig bladder. BJ. Int. 100 (2), 419-429. http://dx.doi.org/10.1111/j.1464-410X.2007.07011.x.
57. Wheeler, M.A., et al., 2002. Prostaglandin E2 production and cyclooxygenase-2 induction in human urinary tract infections and bladder cancer. J. Urol. 168 (4 Pt 1), 1568-1573. http://dx.doi.org/10.1097/01.ju.0000030583.31299.80.
58. Chen, T.C., et al., 2011. Regulation of cyclooxygenase-2 expression in human bladder epithelial cells infected with type I fimbriated uropathogenic E. coli. Cell. Microbiol. 13 (11), 1703-1713. http://dx.doi.org/10.1111/j.1462-5822.2011.01650.x.
59. Poljakovic, M., et al., 2001. Escherichia coli-induced inducible nitric oxide synthase and cyclooxygenase expression in the mouse bladder and kidney. Kidney Int. 59 (3), 893-904. http://dx.doi.org/10.1046/j.1523-1755.2001.059003893.x.
60. Teng, X.W., Abu-Mellal, A.K., Davies, N.M., 2003. Formulation dependent pharmacokinetics, bioavailability and renal toxicity of a selective cyclooxygenase-1 inhibitor SC-560 in the rat. J. Pharm. Pharm. Sci. 6 (2), 205-210.
61. Penning, T.D., et al., 1997. Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib). J. Med. Chem. 40 (9), 1347-1365. http://dx.doi.org/10.1021/jm960803q.
62. Bhowmick, R., et al., 2013. Systemic disease during Streptococcus pneumoniae acute lung infection requires 12-lipoxygenase-dependent inflammation. J. Immunol. 191 (10), 5115-5123. http://dx.doi.org/10.4049/jimmunol.1300522.
63. Bleidorn, J., et al., 2010. Symptomatic treatment (ibuprofen) or antibiotics (ciprofloxacin) for uncomplicated urinary tract infection? - results of a randomized controlled pilot trial. BMC Med. 8, 30. http://dx.doi.org/10.1186/1741-7015-8-30.
64. Kalle, A.M., Rizvi, A., 2011. Inhibition of bacterial multidrug resistance by celecoxib, a cyclooxygenase-2 inhibitor. Antimicrob. Agents Chemother. 55 (1), 439-442. http://dx.doi.org/10.1128/AAC.00735-10.